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Background. To test two different antiemetic regimens for preventing nausea and vomiting in
patients with non-Hodgkin’s lymphoma (NHL) undergoing systemic chemotherapy (CT) with
ProMECE-CytaBOM (P-C).
Patients and Methods. Twenty consecutive untreated adult outpatients with histologically con-
firmed NHL and scheduled to receive P-C chemotherapy were registered in a randomized, double-
blind, cross-over study to compare the antiemetic efficacy of a levosulpiride (LS)-based and metoclo-
pramide (MTC)-based regimen. 
Results. Complete protection from vomiting was recorded in 93% (62/67) of courses with the LS-reg-
imen and in 89% (62/70) with the MTC-regimen (p = 0.428). No nausea was observed in 84% (56/67)
of courses with the LS-regimen and in 74% (52/70) with the MTC-regimen (p = 0.183). No differences
in prevention of emesis were recorded when patients crossed to the other regimen. Both regimens
were well tolerated; however, on day 8 of chemotherapy, when both antiemetic regimens were admin-
istered at a higher dose, the LS-based combination showed significantly lower  toxicity (p = 0.035). 
Conclusions. ProMECE-CytaBOM-induced emesis can be prevented in most cases with appropriate,
specifically designed antiemetic therapy. Both the LS- and MTC-based combinations resulted in a high
percentage of complete protection from emesis. However, the higher incidence of side effects observed
with MTC makes the LS-based regimen preferable for patients receiving P-C chemotherapy.
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T
he combination of prednisone, doxoru-
bicin, cyclophosphamide, and etoposide
followed by cytarabine, bleomycin, vin-
cristine, and methotrexate with leucovorin res-
cue (ProMACE-CytaBOM, P-C)1 represents a
highly effective treatment for patients with ag-
gressive, non-Hodgkin’s lymphomas.2-5
However, P-C chemotherapy (CT) is associat-
ed with several, sometimes dose-limiting side-
effects, including myelosuppression, alopecia,
mucositis, peripheral neurotoxicity, cardiotoxici-
ty, and emesis. 
The emetogenic potential of P-C is mostly due
to doxorubicin and cyclophosphamide on day 1,
and the association of cytarabine, vincristine,
bleomycin and methotrexate on day 8 of each
cycle. On the whole, P-C is regarded as a moder-
ately emetogenic chemotherapeutic program,
and patients treated with this regimen should  be
adequately protected against nausea and vomit-
ing. To date, little information is available on the
efficacy of antiemetic medications for patients
receiving P-C. In a recently published report by
the GISL (Gruppo Italiano per lo Studio dei
Linfomi) on a series of patients treated with P-C,
standard antiemetic protection with metoclo-
pramide (MTC) (Plasil, Lepetit S.p.A., Milano)
and promethazine proved ineffective in over
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50% of cases, especially against drugs delivered
on day 8.5
Levosulpiride (LS) (Levopraid, Ravizza Far-
maceutici S.p.A., Milano) is a benzamide com-
pound with a selective dopamine (D2) receptor
antagonist that has been seen to be highly effec-
tive in the prevention of CT-induced emesis.6
Moreover, compared to MTC, this sulpiride
stereoisomer seems to present a lower toxicity
rate with no extrapyramidal reactions.6
In an effort to minimize acute nausea and
vomiting in patients undergoing chemotherapy
with ProMECE-CytaBOM, we designed a dou-
ble-blind, cross-over study to compare the effi-
cacy and safety of a LS-based and a MTC-based
antiemetic combination. We report here the
final results of this study, concluded after 20
consecutive patients had been enrolled.
Patients and Methods
Twenty consecutive patients with histologically
confirmed, aggressive NHL scheduled to receive
P-C chemotherapy were enrolled. The character-
istics of these patients are summarized in Table
1. To be included in the study patients had to be
at least 18 years of age, have received no prior
CT treatments and be expected to receive at least
four cycles of P-C. Exclusion criteria included
nausea or vomiting or the use of antiemetic
agents in the 24 hours before CT, severe concur-
rent illness or other causes of vomiting, concur-
rent use of benzodiazepines (except when given
for night sedation), and radiotherapy. The study
was approved by the local Ethics Committees of
participating institutions and all patients gave
informed consent.
Study design
In this double-blind, cross-over study patients
were randomly assigned to two different anti-
emetic programs. Patients assigned to Arm A
were to receive two initial cycles of a LS-based
antiemetic regimen followed by two cycles of
MTC-based therapy, while those in Arm B
would be given two initial cycles of a MTC-based
regimen followed by two cycles of LS-based ther-
apy. According to the study design each patient
would be treated with both antiemetic combina-
tions but in a different sequence (LS32 →
MTC32 or MTC32 → LS32.
ProMECE-CytaBOM chemotherapy
Day 1: cyclophosphamide 650 mg/m2; etopo-
side 120 mg/m2; epidoxorubicin 30 mg/m2; day
8: cytosine arabinoside 300 mg/m2; bleomycin 5
mg/m2; vincristine 1.4 mg/m2; methotrexate 120
mg/m2; prednisone 60 mg/m2 orally, day 1-14
(except days 1 and 8 I.V.). ProMECE-CytaBOM
was delivered according to the scheme proposed
by Fisher et al.1 except for doxorubicin which
was replaced at a 20% higher dose by epidoxoru-
bicin. Epidoxorubicin was preferred to doxoru-
bicin in view of its lower cardiac toxicity at the
same tumor effectiveness.7
Antiemetic regimen
Levosulpiride-regimen → day 1: LS (0.5 mg/kg
in 100 cc saline) over 15 minutes, 30 minutes
before and 30 minutes after CT; prochlorper-
azine (10 mg rectally) 30 minutes before CT; day
8: chlordimethyldiazepam (1 mg orally) 45 min-
utes before CT; LS (1 mg/kg in 100 cc saline)
over 15 minutes, 30 minutes before and 30 min-
utes after CT; promethazine (50 mg intramuscu-
larly) 45 minutes before CT; prochlorperazine
(10 mg rectally) 30 minutes before CT.
Metoclopramide-regimen: → same combina-
tion of drugs as Arm A, except LS was replaced
with MTC at the same dose.
No other antiemetic agents were given during
the 24 hours following chemotherapy. Food
Prevention of ProMECE-CytaBOM-induced emesis
LEVO MTC
No. of courses % No. of courses  %
age (yr)
 50 1 11 3 27
> 50 8 89 8 73
performance status (WHO)
0 1 12 8 73
1 4 44 2 19
2 4 44 1 8
sex
male 3 33 4 36
female 6 67 7 64
Table 1. Patient characteristics.
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intake was forbidden in the 6 hours following
CT administration. Before discharge, patients
were asked about the tolerability of the therapy
received. Twenty-four hours after the treatment
patients were contacted by phone by a member
of the research team who recorded the number
of emetic episodes, nausea, and any other
adverse events.
The efficacy, tolerability and safety of the anti-
emetic regimens were recorded for each course
(day 1 or day 8 of P-C) of chemotherapy. 
Response was defined according to the follow-
ing criteria: complete protection (no emetic
episodes), partial protection (one to three emetic
episodes), or equivocal protection (four or more
emetic episodes). An emetic episode was defined
as a single vomit or retching (vomit not produc-
ing liquid) or any number of continuous vomits
or retching. Patients not responding to the anti-
emetic regimens (i.e. 5 or more emetic episodes
in any day after CT) received rescue medication
(dexamethasone 8 mg intramuscularly, repeated
every 12 hours as needed) and were removed
from the study. 
The grade of nausea was assessed using the fol-
lowing scale: none, no nausea; mild nausea, no
interference with normal daily life; moderate
nausea, interference with normal daily life; and
severe, bedridden due to nausea. Nausea is
defined as the sensation of imminent vomiting.
All data were analyzed with the Statistical
Package for Social Sciences (SPSS).8 Differences
between groups were assessed using the chi-
square test or Fisher’s exact test. Grades were
grouped when there were too few patients with
higher grades.
Results
Six patients in Arm A and 7 in Arm B com-
pleted the planned four cycles of CT. In addition,
3 patients in Arm A and 4 in Arm B received at
least one course of CT. 
Twenty-three courses (8 LS and 15 MTC)
were not assessable due to reduced doses of the
antineoplastic therapy. Thus a total of 137
courses of antiemetic prophylaxis (70 courses
on day 1 and 67 courses on day 8) were avail-
able for the present analysis.
Nausea
On day 1, no nausea was registered in 82% of
the LS-based and 78% of the MTC-based
courses, with no statistically significant differ-
ences (p=0.386). On day 8, complete protection
was achieved in 85% of the LS-based and 71%
of MTC-based courses (p=0.238) (Table 2).
Vomiting
On day 1, complete protection from vomiting
was observed in 97% of the LS-based and in
92% of the MTC-based courses. Differences
were not significant (p=0.139). On day 8, com-
plete protection was recorded in 88% and 85%
of the LS and MTC-based courses, respectively
(p=0.345) (Table 3).
Complete protection from nausea was
observed in 79% (108/137) of all courses, and
complete protection from vomiting in 91%
(124/137). Complete protection from nausea
and vomiting was achieved in 75% (103/137) of
all courses.
Table 2. Protection from nausea.
Day 1 Day 8
No. of courses (%) No. of courses (%)
grade of nausea LEVO MTC p LEVO MTC p
none 28 (82) 28 (78) 0.386 28 (85) 24 (71) 0.238
mild 5 (15) 6 (17) 4 (12) 9 (26)
moderate – 2 (5) – 1 (3)
severe 1 (3) – 1 (3) –
Table 3. Protection from vomiting.
Day 1 DAY 8
No. of courses (%) N. of courses (%)
LEVO MTC p LEVO MTC p
CP 33 (97) 33 (92) 0.139 29 (88) 29 (85) 0.345
PP – 3 (8) 4 (12) 3 (9)
EP 1 (3) – – 2 (6)
CP: complete protection; PP: partial protection; EP: equivocal protection.
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During the first two cycles of P-C no nausea
was registered in 76% (58/76) and no vomiting
in 92% (70/76) of courses, respectively.
Complete protection from nausea or vomiting
was achieved in 75% (57/76) of courses. During
the third and fourth cycles, complete protection
from nausea and vomiting was achieved in 82%
(50/61) and 89% (54/61) of courses, respective-
ly; complete protection from nausea or vomit-
ing  was achieved in 75% (46/61) of courses. 
No nausea was observed in 84% (56/67) of
courses with the LS-regimen and in 74%
(52/70) of those with the MTC-regimen (p =
0.183). As regards emetic episodes, complete
protection was recorded in 93% (62/67)  of  LS-
regimen courses and in 89% (62/70) of those
with the MTC-regimen (p=0.428). 
During the first two cycles 94% of patients
treated with LS and 77% of those treated with
MTC experienced complete protection; the dif-
ferences between the groups was not statistically
significant (p = 0.130). In patients treated with
the LS-based combination, a slight decrease in
protection from emesis was observed over the
courses. During the third and fourth cycles
complete protection from nausea and vomiting
was observed in 75% of patients treated with LS
and in 77% of those treated with MTC; howev-
er,  cross-over did not modify the efficacy of the
antiemetic regimens (Table 4).
Both the LS- and MTC-based antiemetic
combinations were well tolerated, and adverse
events were mild (Table 5). However, a sub-set
analysis showed that on day 8, when antiemetic
drugs were used at a higher dose, the LS-based
regimen was associated with a statistically sig-
nificant lower toxicity rate (p = 0.035). 
Discussion
Controlling of emesis is an important goal in
the supportive care of patients with cancer. This
randomized, double-blind, cross-over study
demonstrated that the combination of chlor-
dimethyldiazepam, prochlorperazine, promet-
hazine,andLS is very effectiveagainst ProMECE-
CytaBOM-induced nausea and vomiting.
To our knowledge, this is the first study
reporting the efficacy of an antiemetic regimen
designed specifically for patients undergoing
chemotherapy for NHL.
ProMECE-CytaBOM is a moderately emeto-
genic chemotherapy regimen comparable to
other commonly used CT combinations con-
taining an anthracycline and/or cyclophos-
phamide. In a previous study we reported that a
combination of metoclopramide and promet-
hazine failed to control P-C-induced emesis in
over 50% of patients.5 In that report we also
observed that drugs administered on day 8 of
Day 1 Day 8
Cycle LS (%) MTC (%) LS (%) MTC (%)
CP nausea 1 8 (89) 9 (82) 9 (100) 8 (73)
2 8 (89) 7 (70) 5 (62) 4 (44)
3 6 (67) 8 (100) 7 (78) 7 (87)
4 6 (86) 5 (71) 7 (100) 4 (67)
CP vomiting 1 9 (100) 10 (91) 9 (100) 10 (91)
2 9 (100) 8 (80) 7 (87) 8 (89)
3 8 (89) 8 (100) 8 (89) 7 (87)
4 7 (100) 6 (86) 5 (71) 5 (83)
CP nausea and 1 8 (89) 9 (82) 9 (100) 8 (73)
vomiting 2 8 (89) 6 (60) 5 (62) 4 (44)
3 6 (67) 8 (100) 6 (67) 6 (75)
4 6 (86) 5 (71) 5 (71) 4 (67)
Table 4. Cross-over evaluation of prophylaxis of ProMECE-CytaBOM-
induced vomiting and nausea.





LEVO MTC  p LEVO MTC p
Sedation – – 1 2
Diarrhea 1 – – 1
Confusion – – – 1
Extrapyramidal
reactions
– 3 – 1
Hot-flushes 1 – – 1
Agitation 1 1 1 2
Hiccupping 1 1 1 2
Total 4 5 0.790 3 10
Table 5. Adverse events.
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ProMECE-CytaBOM were  associated with a
higher incidence of emesis than those given on
day 1, suggesting that the emetogenic potential
of the CT combination (cytarabine, vincristine,
bleomycin and methotrexate) on day 8 might be
schedule dependent. Therefore on day 8 of this
study patients were to receive a different anti-
emetic scheme, with a higher dose of benzamide
(LS or MTC) in addition to chlordimethyldia-
zepam and promethazine.
The complete protection from acute vomiting
in 93% of courses achieved with LS and pro-
chlorperazine on day 1, and with chlordime-
thyldiazepam, LS, prochlorperazine and
promethazine on day 8 of ProMECE-CytaBOM
should be considered an extremely remarkable
result. Indeed, with serotonin receptor antago-
nists (a newer class of antiemetic agents), the
rate of complete protection from emesis in
patients treated with cyclophosphamide (≥ 600
mg/m2, in combination)- or anthracycline-
based regimens usually does not exceed 70-
86%.9-12
Both levosulpiride, a selective dopamine (D2)
receptor antagonist, and MTC have already
been reported to be effective agents in the pre-
vention of acute chemotherapy-induced
emesis.6,14 Moreover, LS exerts its antiemetic
action without sedation or extrapyramidal
reactions, side effects which often complicate
the administration of MTC.14
In the present study, adverse events with both
antiemetic combinations were mild; however,
the percentage of patients experiencing side
effects differed between the two groups. The
number of patients complaining of adverse
experiences on day 8 was significantly higher in
the MTC group (p = 0.035). In particular, no
patient in the LS group complained of extra-
pyramidal reactions, whereas 6% of those
receiving MTC (p = 0.148) experienced such a
reaction.
Finally, it must be noted that the cost of the
combination used in the present study is very
low (less than $3 on day 1 and less than $6 on
day 8), far less than that of low-dose serotonin
antagonist-based regimens ($44 per day).
In conclusion, the very high complete protec-
tion rate, the absence of distressing extrapyra-
midal reactions, and the low cost make the LS-
based regimen particularly recommendable for
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